Pharma Journalist -

The European Commission has announced a €225 million investment aimed at accelerating the development of next-generation influenza vaccines capable of providing broader protection…
Read More...

AbbVie has announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for the combination of VENCLEXTA® (venetoclax) and acalabrutinib…
Read More...

Clinical-stage biotech VivaMed BioPharma has entered into a strategic partnership with Syngene International, a global contract research, development and manufacturing organization…
Read More...

Merck & Co., Inc., known as MSD outside the United States and Canada, has entered into a major research and development agreement with Mayo Clinic to apply artificial intelligence…
Read More...

Novartis has announced positive topline results from its pivotal Phase III RemIND trial evaluating oral remibrutinib in patients with chronic inducible urticaria (CIndU), a condition…
Read More...

Johnson & Johnson has unveiled new data from its Phase 1b/2 OrigAMI-4 study, demonstrating that first-line treatment with investigational subcutaneous amivantamab and…
Read More...

Boehringer Ingelheim India Private Limited has signed a Memorandum of Understanding (MoU) with National Institute of Pharmaceutical Education and Research, Raebareli (NIPER Raebareli),…
Read More...

Catalent and S.Biomedics have entered into a strategic partnership to advance the development and manufacturing of TED-A9, an investigational allogeneic pluripotent stem cell-derived…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further…
Read More...

Unnatural Products, Inc. (UNP), a biotechnology company focused on developing orally delivered macrocyclic peptides for hard-to-drug targets, has entered into a research collaboration…
Read More...